InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: None

Monday, 10/31/2016 1:14:46 PM

Monday, October 31, 2016 1:14:46 PM

Post# of 48316
Update to Clinical Pipeline-

(Metastatic Melanoma trial)-

Phase II study to assess the safety and efficacy of multiple treatment cycles of ImmunoPulse® IL-12 monotherapy in patients with in-transit cutaneous and subcutaneous metastatic melanoma. Patients are currently being enrolled into an extension arm of the study to evaluate a new six-week treatment cycle.

Apparently Oncosec is not abandoning the EP-IL12 as a monotherapy.